Latest News
Web Date: June 7, 2006

FDA Approves Resumed Sale Of MS Drug

Tysabri will be allowed back on the market, but agency imposes restrictions on distribution
Department: Government & Policy

A multiple sclerosis (MS) drug withdrawn from the market for a year because of a rare but serious side effect will be allowed to return under a restricted distribution program designed to help ensure safe use of the product, federal health officials said on June 5.

FDA says Cambridge, Mass.-based Biogen Idec and Ireland's Elan Corp. can resume marketing Tysabri, a monoclonal antibody used by patients with relapsing forms of . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society